Presynaptic Glutamatergic Dysfunction in Bipolar Disorder

Biological Psychiatry

Volumn 67, Issue 11, 2010, Pages 1007-1009

  Chen, Guang ^a   Henter, Ioline D ^a   Manji, Husseini K ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; GLUTAMATE AMMONIA LIGASE; GLUTAMATE RECEPTOR; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; GLUTAMINE; IONOTROPIC RECEPTOR; LITHIUM CHLORIDE; MESSENGER RNA; METABOTROPIC RECEPTOR; NETRIN; NEUROTRANSMITTER; VALPROIC ACID; VESICULAR GLUTAMATE TRANSPORTER 1; VESICULAR GLUTAMATE TRANSPORTER 2;

ARTICLE; BIPOLAR DISORDER; COGNITION; FUNCTIONAL DISEASE; HUMAN; MAJOR DEPRESSION; MOOD DISORDER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; RELAPSE;

EID: 77951800184     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2010.03.027     Document Type: Note

References (17)

1. Eastwood S.L., and Harrison P.J. Markers of glutamate synaptic transmission and plasticity are increased in the anterior cingulate cortex in bipolar disorder. Biol Psychiatry 67 (2010) 1010-1016
2. Sanacora G., Zarate C.A., Krystal J.H., and Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 7 (2008) 426-437
3. Kwon S.K., Woo J., Kim S.Y., Kim H., and Kim E. Trans-synaptic adhesions between netrin-G ligand-3 (NGL-3) and receptor tyrosine phosphatases lar, PTP{delta}, and PTP{Sigma} via specific domains regulate excitatory synapse formation. [published online ahead of print February 6]. J Biol Chem (2010)
4. Hashimoto K., Sawa A., and Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 62 (2007) 1310-1316
5. Lan M.J., McLoughlin G.A., Griffin J.L., Tsang T.M., Huang J.T., Yuan P., et al. Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder. Mol Psychiatry 14 (2009) 269-279
6. Bendikov I., Nadri C., Amar S., Panizzutti R., de Miranda J., Wolosker H., et al. A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr Res 90 (2007) 41-51
7. Ongur D., Jensen J.E., Prescot A.P., Stork C., Lundy M., Cohen B.M., et al. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry 64 (2008) 718-726
8. Dager S.R., Friedman S.D., Parow A., Demopulos C., Stoll A.L., Lyoo I.K., et al. Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry 61 (2004) 450-458
9. Frye M.A., Watzl J., Banakar S., O'Neill J., Mintz J., Davanzo P., et al. Increased anterior cingulate/medial prefrontal cortical glutamate and creatine in bipolar depression. Neuropsychopharmacology 32 (2007) 2490-2499
10. Frey B.N., Stanley J.A., Nery F.G., Monkul E.S., Nicoletti M.A., Chen H.H., et al. Abnormal cellular energy and phospholipid metabolism in the left dorsolateral prefrontal cortex of medication-free individuals with bipolar disorder: An in vivo 1H MRS study. Bipolar Disord 9 suppl 1 (2007) 119-127
11. Colla M., Schubert F., Bubner M., Heidenreich J.O., Bajbouj M., Seifert F., et al. Glutamate as a spectroscopic marker of hippocampal structural plasticity is elevated in long-term euthymic bipolar patients on chronic lithium therapy and correlates inversely with diurnal cortisol. Mol Psychiatry 14 (2009) 696-704 647
12. Garcia-Garcia A.L., Elizalde N., Matrov D., Harro J., Wojcik S.M., Venzala E., et al. Increased vulnerability to depressive-like behavior of mice with decreased expression of VGLUT1. Biol Psychiatry 66 (2009) 275-282
13. Moutsimilli L., Farley S., Dumas S., El Mestikawy S., Giros B., and Tzavara E.T. Selective cortical VGLUT1 increase as a marker for antidepressant activity. Neuropharmacology 49 (2005) 890-900
14. Uezato A., Meador-Woodruff J.H., and McCullumsmith R.E. Vesicular glutamate transporter mRNA expression in the medial temporal lobe in major depressive disorder, bipolar disorder, and schizophrenia. Bipolar Disord 11 (2009) 711-725
15. Eastwood S.L., and Harrison P.J. Decreased mRNA expression of netrin-G1 and netrin-G2 in the temporal lobe in schizophrenia and bipolar disorder. Neuropsychopharmacology 33 (2008) 933-945
16. Du J., Creson T.K., Wu L.J., Ren M., Gray N.A., Falke C., et al. The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. J Neurosci 28 (2008) 68-79
17. Schloesser R.J., Huang J., Klein P.S., and Manji H.K. Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 33 (2008) 110-113